Patient case: 70-year-old male with non-small cell lung cancer; genetic feature: KRAS (G12C)

Clinical trial: Recurrent Predictive Power of Circulating Tumor Cell in Non Small Cell Lung Cancer Patients Who Receive Curative Resectionresection

Summary: From literature review, circulating tumor cell was demonstrated its possible role in disease relapse. It was rare nit could be identified in all lung cancer patients. In addition, circulating tumor cell usual aggregate to form circulating tumor micro-emboli and caused distant metastases. Therefore, circulating tumor cell could play a role in detect disease relapse and appropriate treatment could be given more earlier and further prolong patients' survival. However, the detail clinical significance of circulating tumor still remains unknown. The aim of this study was evaluate the clinical significance, including present timing, numbers, and correlation to disease relapse, of circulating tumor cell in lung cancer patients. The investigators want to clarify the clinical significance between circulating tumor cell and clinical presentation of lung cancer in order to establish new prediction model and improve lung cancer patients' survival.

Detailed description: -  Study Design
  1. Duration of Treatment: 2018/8/1~2021/7/31
  2. Recruitment: Volunteer after explaination
  3. Number of Planned Patients: 200 According to the data base of lung cancer registry of Chang Gung Memorial Hospital, Linkou. The patients' composition of lung cancer was 280 in stage 1, 45 in stage 2 and 45 in stage 3, respectively. Estimated patient number in disease severity
  1. Stage 1: 100
  2. Stage 2: 50
  3. Stage 3: 50 4. Measurement, Estimate recruitment, and risk
  Study subject:
  1. Non small lung cancer patients
  2. Received curative intended tumor resection (ie. anatomic resection and mediastinal lymph node dissection)
  3. age ≧ 20 yeas old
  4. agreed to join the study after thoroughly explanations Data collection: medical record review and blood sampling for circulating tumor cell purification Risk: no increased for patients who join into the study 5. Inclusion criteria
  1. Non small cell lung cancer patients ( ≧20 years old) clinical stage I to IIIa
  2. Volunteer to join the study after thoroughly explanations 6. Exclusion criteria
  1. Small cell lung cancer component which identified in pathology
  2. Patients who presented as stage IIIb or IV
  3. Not received curative intended surgery due to multi-comorbidities
  4. Patients who presented in tumor seeding or positive resection in pathology confirmation
  5. Patients who received neoadjuvant therapy 7. Timing of blood sampling: Pre-operation, discharge date, and the regular OPD surveillance date (3 month-interval) 8. Blood sampling: 20 ml blood that withdrawal from peripheral vein 9. Blood sampling time: less than 3 minutes 10. Sample examination: Purification circulating tumor cell by high sensitive tumor cell marker. Combine the medical record to analyze the relationship between circulating tumor cell and disease relapse 11. Preservation of sample: All sample would be used to purify circulating tumor cell as soon as possible after collected. No sample left after circulating tumor cell purification.

Eligibility: Inclusion Criteria:
  -  Non small cell lung cancer patients ( ≧20 years old) clinical stage I to IIIa
  -  Volunteer to join the study after thoroughly explanations
  Exclusion Criteria:
  -  Small cell lung cancer component which identified in pathology
  -  Patients who presented as stage IIIb or IV
  -  Not received curative intended surgery due to multi-comorbidities
  -  Patients who presented in tumor seeding or positive resection in pathology confirmation
  -  Patients who received neoadjuvant therapy

Relevance to patient case: not relevant